Holen Sie sich die Stockscreener-App
9.97
0.50%
0.05
Handel nachbörslich:
10.00
0.03
+0.30%
Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten
BioCryst targets $1B in global ORLADEYO revenue by 2029 amid 33-37% projected growth this year - MSN
Best Momentum Stocks to Buy for May 9th - The Globe and Mail
New Strong Buy Stocks for May 9th - The Globe and Mail
Mariner LLC Buys 3,224 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
Transcript : BioCryst Pharmaceuticals, Inc. Presents at The Citizens JMP Life Sciences Conference 2025, May-08-2025 09 - marketscreener.com
Why BioCryst (BCRX) Might be Well Poised for a Surge - Yahoo Finance
What Makes BioCryst Pharmaceuticals (BCRX) a Strong Momentum Stock: Buy Now? - Yahoo Finance
BioCryst at Citizens JMP: Orlodayo’s Market Growth and Pipeline Prospects - Investing.com
BioCryst at Citizens JMP: Orlodayo’s Market Growth and Pipeline Prospects By Investing.com - Investing.com UK
Does BioCryst (BCRX) Have the Potential to Rally 61.21% as Wall Street Analysts Expect? - Yahoo Finance
Biocryst seeks FDA OK of Orladeyo for HAE patients as young as 2 - Angioedema News
Analysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest Results - Yahoo Finance
Barclays Raises BioCryst Pharma (BCRX) Price Target to $11 | BCR - GuruFocus
Barclays Raises BioCryst Pharma (BCRX) Price Target to $11 | BCRX Stock News - GuruFocus
Barclays Raises Price Target for BioCryst (BCRX), Highlights Growth Prospects | BCRX Stock News - GuruFocus
BioCryst Pharmaceuticals (BCRX) Reports Break-Even Earnings for Q1 - MSN
BioCryst Pharmaceuticals’ SWOT analysis: stock outlook amid HAE market growth - Investing.com Nigeria
BioCryst Pharma (BCRX) Sees Price Target Boost from RBC Capital - GuruFocus
BioCryst Pharma (BCRX) Sees Price Target Boost from RBC Capital | BCRX Stock News - GuruFocus
BioCryst Pharma (BCRX) Price Target Raised by JP Morgan | BCRX Stock News - GuruFocus
BCRX Price Target Raised as BioCryst Shows Strong Fundamentals | - GuruFocus
BioCryst Pharma (BCRX) Maintains Buy Rating with $30 Price Targe - GuruFocus
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2025 Earnings Call Transcript - Insider Monkey
RBC Raises Price Target on BioCryst Pharmaceuticals to $13 From $11, Keeps Outperform Rating - marketscreener.com
BCRX Stock: BioCryst's Price Target Raised with Positive Revenue - GuruFocus
When (BCRX) Moves Investors should Listen - news.stocktradersdaily.com
Why These 10 Firms Soared on Monday - Insider Monkey
BCRX: Needham Raises Price Target for BioCryst Pharma to $17 | B - GuruFocus
Why BioCryst Pharmaceuticals, Inc. (BCRX) Soared on Monday - Yahoo Finance
BioCryst stock target to $14 on Orladeyo sales, maintains Buy By Investing.com - Investing.com Nigeria
BioCryst Pharmaceuticals Inc (BCRX) Q1 2025 Earnings Call Highlights: Strong ORLADEYO Sales ... - Yahoo Finance
BioCryst Pharmaceuticals Inc (BCRX) Q1 2025 Earnings Call Highli - GuruFocus
Earnings call transcript: BioCryst’s Q1 2025 revenue and stock surge By Investing.com - Investing.com Nigeria
BioCryst (BCRX) Surges with ORLADEYO Revenue and Debt Reduction Efforts - GuruFocus
BioCryst Pharmaceuticals Reports Strong Q1 2025 Growth - TipRanks
BioCryst Shares Surge To 16-Month High On Strong Q1 Results: Retail Sentiment Turns Extremely Bullish - MSN
BioCryst Pharmaceuticals (BCRX) Boosts Revenue Guidance on Stron - GuruFocus
BioCryst Pharmaceuticals Soars 23% In One SessionHere's Why It Surprised Investors - Benzinga
BioCryst Pharmaceuticals (BCRX) Boosts Revenue Guidance on Strong ORLADEYO Sales - GuruFocus
Top Midday Gainers - marketscreener.com
BioCryst: Strong Opportunity For A Double With A Proven Therapy (BCRX) - Seeking Alpha
BioCryst Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Crude Oil Falls Over 2%; ISM Services PMI Rises In April - Benzinga
BioCryst Pharmaceuticals surges 2% on strong Q1 results, raised outlook By Investing.com - Investing.com Nigeria
BioCryst Pharmaceuticals (BCRX) Surges on Q1 Earnings Beat: What Traders Need to Know - RagingBull
BioCryst Pharmaceuticals (BCRX) Boosts Revenue Forecast Amid Strong Q1 Results - GuruFocus
BioCryst Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:BCRX) - Seeking Alpha
BioCryst stock jumps on raised guidance, strong Q1 report - Seeking Alpha
Napco Security Technologies Posts Better-Than-Expected Results, Joins Skechers, BioCryst Pharmaceuticals And Other Big Stocks Moving Higher On Monday - Benzinga
BioCryst Hikes on Q1 Figures - Baystreet.ca
Earnings call transcript: BioCryst’s Q1 2025 revenue and stock surge - Investing.com
BioCryst Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
BioCryst Q1 2025 slides: ORLADEYO sales surge, guidance raised By Investing.com - Investing.com Canada
BioCryst Pharma Stock Soars 10% Pre-Market On Upbeat Q1 Earnings, Improved Full Year Guidance: Retail’s Pleased - MSN
BioCryst Pharmaceuticals (BCRX) Surpasses Q1 Expectations, Raises 2025 Forecast - GuruFocus
BioCryst Reports Strong Q1 2025 Financial Performance - TipRanks
BioCryst Pharmaceuticals Inc Q1 2025 Earnings: EPS at $0.00 Beats Estimate, Revenue Surges to $145.5 Million Exceeding Expectations - GuruFocus
BioCryst (BCRX) Boosts 2025 Revenue Forecast for ORLADEYO | BCRX Stock News - GuruFocus
BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update - ADVFN
BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update | BCRX Stock News - GuruFocus
(BCRX) BioCryst Pharmaceuticals Expects 2025 Revenue Range $580M$600M, vs. FactSet Est of $563.6M - marketscreener.com
Earnings Flash (BCRX) BioCryst Pharmaceuticals Posts Q1 EPS $0.00, vs. FactSet Est of $0.07 Loss - marketscreener.com
0.82%
1.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):